<DOC>
	<DOC>NCT01149057</DOC>
	<brief_summary>This single arm, open-label study will evaluate the efficacy and safety of RoActemra/Actemra (tocilizumab) in patients with active, moderate to severe rheumatoid arthritis who have an inadequate response to non-biologic and/or biologic disease-modifying antirheumatic drugs (DMARDs). Patients will receive intravenous RoActemra/Actemra at a dose of 8 mg/kg every 4 weeks. Anticipated time on study treatment is 96 weeks.</brief_summary>
	<brief_title>A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic and/or Biologic DMARDS</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Adult patients, &gt;/=18 years of age Active moderate to severe rheumatoid arthritis Inadequate response to &gt;/=3 DMARDs (nonbiologic and/or biologic) Current treatment at stable dose for &gt;/=8 weeks Etanercept discontinued &gt;/=2 weeks, Anakinra &gt;/=1 week, Infliximab, Adalimumab, Abatacept, Golimumab, Certolizumab &gt;/=4 weeks, prior to baseline visit. Patients have discontinued MabThera/Rituxan or Ocrelizumab &gt;/=16 weeks, and must have proven Bcell repletion Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following baseline Rheumatic autoimmune disease other than RA Functional class IV (American College of Rheumatology Classification) Prior history or current inflammatory joint disease other than RA Oral corticosteroids at a dose of &gt;10 mg/day prednisone equivalent Positive hepatitis B surface antigen (HBsAg) and / or total hepatitis B core antibodies (HBcAb) or hepatitis C virus (HCV) antibody Current or history of recurrent bacterial, viral, fungal or mycobaterial infection History of or currently active primary or secondary immunodeficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>